Aggressive pharmacological treatment for reversing malignant bowel obstruction

Mercadante, Sebastiano; Ferrera, Patrizia; Villari, Patrizia; Marrazzo, Antonio

doi:10.1016/j.jpainsymman.2004.01.007

Cited by 101 publications

(76 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These effects of octreotide lead to alleviation of MBO symptoms by limiting the vicious cycle of distention and secretion (Khoo et al, 1994;Ripamonti and Mercadante, 2005;Mercadante et al, 2007;Mercadante and Porzio, 2012). The efficacy of octreotide in MBO management has been frequently reported in gastrointestinal and ovarian cancers, but not in urological cancer Mystakidou et al, 2002;Mercadante et al, 2004).…”

Section: Mbo Is a Common Complication In Patients Withmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Impact of Palliative Treatment Using Octreotide for Inoperable Malignant Bowel Obstruction Caused by Advanced Urological Cancer

Kubota¹,

Taguchi²,

Kobayashi³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Mbo Is a Common Complication In Patients Withmentioning

confidence: 99%

“…Certain reports suggest that administration of dexamethasone alone is effective in controlling MBO symptoms (Mercadante et al, 2004;Tuca et al, 2012). However, the effects of octreotide and corticosteroids on MBO have not been compared.…”

Section: Mbo Is a Common Complication In Patients Withmentioning

confidence: 99%

Clinical Impact of Palliative Treatment Using Octreotide for Inoperable Malignant Bowel Obstruction Caused by Advanced Urological Cancer

Kubota¹,

Taguchi²,

Kobayashi³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…It is a key drug for cancerous, peritonitis−related obstruction of the digestive tract 4,5) . In terminal cancer patients with obstruction of the digestive tract, early combination therapy with OCT and dexamethasone sodium phosphate (DEX) reduces oedema of the digestive tract, decreasing digestive tract pressure and relieving obstruction 6) . These 2 agents are frequently administered together for palliative care.…”

Section: -3)mentioning

confidence: 99%

Effect of sodium bisulphate on the stability of octreotide acetate: compatibility study with dexamethasone injection

Tanabe¹,

Ohkubo²,

Ikezaki³

et al. 2013

Palliat Care Res

View full text Add to dashboard Cite

Background: Although several dexamethasone phosphate preparations are commercially available and frequently administered with octreotide acetate, their compatibility remains unknown. Aim: We investigated the effect of pH and sodium bisulphate on the stability of octreotide acetate. Measurement design: Octreotide acetate percentage was measured 3 and 10 days after it was mixed with 2 dexamethasone phosphate preparations containing different concentrations of sodium bisulphate as an additive, and in one that did not contain sodium bisulphate. Solutions were also analysed after they were prepared using phosphate buffer to achieve pH values of 4.0, 7.0, and 9.0. The initial octreotide acetate concentration was 41.7 g/mL. High−performance liquid chromatography was used for measurement. Results: The octreotide acetate percentage in the mixture with dexamethasone phosphate without sodium bisulphate was maintained at 95% for up to 10 days. However, mixing octreotide acetate with the other 2 agents resulted in a significant decrease to 85%. The octreotide acetate percentage was ＜90% after sodium bisulphate−containing solution was stored at room temperature under light−protected conditions for 3 days. The percentage of octreotide acetate in the pH 7.0 solution was ＜90% three days after preparation; however, in the pH 4.0 solution, it was maintained at 95% for up to 10 days. Conclusions: Our results suggest that octreotide acetate is hydrolysed in the presence of sodium bisulphate, leading to a decrease in the percentage of octreotide acetate in the solution, which can be avoided using sodium bisulphate−free dexamethasone phosphate preparations. Palliat Care Res 2013; 8(2): 177−83

show abstract

“…In combination with other agents, it has been found to be effective in the recovery of bowel transit in most patients. 8 The aim of this study was to prospectively evaluate the effectiveness of AM in patients unresponsive to current laxatives. The secondary outcome was to assess the tolerability of this agent.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and Tolerability of Amidotrizoate for the Treatment of Constipation Resistant to Laxatives in Advanced Cancer Patients

Mercadante

Ferrera

Casuccio

2011

Journal of Pain and Symptom Management

Self Cite

View full text Add to dashboard Cite

Context. Constipation is a common problem for advanced cancer patients, and is generally inadequately treated.Objectives. The aim of this study was to prospectively evaluate the effectiveness and tolerability of amidotrizoate (AM) in patients unresponsive to current laxatives.Methods. A consecutive sample of advanced cancer patients was surveyed. Inclusion criteria were no bowel movements for three days despite receiving regular doses of senna or lactulose. AM 50 mL was administered orally; the dose could be repeated the day after, based on clinical judgment and/or patients' preference. Age, sex, primary tumor, previous abdominal surgery, chemotherapy and radiotherapy performed in the previous month, and the use of opioids were recorded. Nausea, the presence of early satiety, and fluid and food intake also were measured. Time to first bowel movement was recorded, and adverse effects attributable to AM.Results. Ninety-nine patients were surveyed (36 women/63 men). The mean age was 65.7 years (SD AE 12.2) and the mean Karnofsky score was 46.8 (SD AE 9.4). Patients had no bowel movement for a mean of four days (SD AE 1.8, range 3e15 days). A total of 80.8% of patients were receiving opioids in doses of mean daily oral morphine equivalents of 164 mg (SD AE 235). After AM administration (mean 9.9 AE 6.5 hours), 44.4% of patients had a bowel movement within 24 hours. This effect was associated with significant improvement of other symptoms and was independent of age (P ¼ 0.513), gender (P ¼ 0.090), Karnofsky status (P ¼ 0.979), days of constipation (P ¼ 0.198), concomitant chemotherapy (P ¼ 0.098) or radiotherapy (P ¼ 0.414), the use of opioids (P ¼ 0.361), opioid doses (P ¼ 0.420), and primary tumor (P ¼ 0.231). The treatment was more effective in patients who had previous abdominal surgery (HR ¼ 3.33).

show abstract

Aggressive pharmacological treatment for reversing malignant bowel obstruction

Cited by 101 publications

References 16 publications

Clinical Impact of Palliative Treatment Using Octreotide for Inoperable Malignant Bowel Obstruction Caused by Advanced Urological Cancer

Clinical Impact of Palliative Treatment Using Octreotide for Inoperable Malignant Bowel Obstruction Caused by Advanced Urological Cancer

Effect of sodium bisulphate on the stability of octreotide acetate: compatibility study with dexamethasone injection

Effectiveness and Tolerability of Amidotrizoate for the Treatment of Constipation Resistant to Laxatives in Advanced Cancer Patients

Contact Info

Product

Resources

About